Due to the initial success, Ad-p53 therapies gained a surplus of attention, and by 2005, 58 recombinant Ad-p53 therapies had reached trials for over 20 types of cancers, including Advexin and SCH-58500 for ovarian cancer [85,86,87]. This evidence concerns the gene TP53 and ovarian cancer.